Skip to content

Congress Highlights​

We are delighted to present to you the highlights from the most updated research results

in the scleroderma field presented at international congresses:

a selection from oral and poster presentation sessions.

Highlights from ACR 2023 - San Diego

Highlights from EULAR Congress 2023 - Milan

Highlights from ACR Philadelphia 2022

Highlights from the EULAR 2018

Clinical Practice

A EUSTAR Young lnvestigator Group Report

Exciting clinical research was presented at the meeting, especially advances in the fields of imaging, risk prediction models and more personalised approaches to intervention for patients with SSc.

Basic Science

A EUSTAR Young lnvestigator Group Report

A large number of exciting abstracts
foccusing on basic science in the field of systemic sclerosis (SSc) were presented at the EULAR 2018 meeting. This article presents a summary of small selection of excellent work presented at the meeting.

Clinical Trials and Therapeutics

A EUSTAR Young lnvestigator Group Report

A large amount of new clinical research was presented at the EULAR 2018 annual meeting. Here we present a brief summary of some selected abstracts focusing on new potential therapeutic approaches for Systemic Sclerosis (SSc) and its complications.

Highlights from the ACR Congress 2017

Clinical Practice

A EUSTAR Young lnvestigator Group Report

A large amount of new clinical research was presented at the meeting that has the potential to deliver novel biomarkers, improved risk prediction models and more personalised approaches to intervention for patients with SSc over the coming years.

Basic Science

A EUSTAR Young lnvestigator Group Report

Sixty-two basic science abstracts were presented at the meeting. The following selection provides a synopsis of some of the recurring themes and notable findings reported at the meeting.

Clinical Trials and Therapeutics

A EUSTAR Young lnvestigator Group Report

The 2017 ACR meeting saw the reporting of a large number of interesting clinical trials that could result in new therapeutic options for patients with SSc over the coming years.

© 2023 European Scleroderma Trials and Research Group (EUSTAR)